Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer
Research Grant
Administered By
Pharmacology & Cancer Biology
Awarded By
Massachusetts General Hospital
Start Date
March 1, 2023
End Date
December 31, 2026
Administered By
Pharmacology & Cancer Biology
Awarded By
Massachusetts General Hospital
Start Date
March 1, 2023
End Date
December 31, 2026